Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Borrello IM et al. - A decrease in WT1 transcripts in blood was noted in 69% of patients following the first immunotherapy dose and was also associated with longer 3-year RFS (61% vs. 0%). In conclusion, immunotherapy in combination with primed lymphocytes and ASCT shows encouraging signals of potential activity in AML.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address